Stockscreener 앱 받기
40.47
19.66%
6.65
시장 영업 전:
40.06
-0.41
-1.01%
Corcept Therapeutics Inc 주식(CORT)의 최신 뉴스
What Makes Corcept A Stock To WatchA Perfect Mix Of Growth, Cash, And Trial Catalysts - RTTNews
CORT Stock Skyrockets 35% After Early FDA Nod For Ovarian Cancer Drug - Stocktwits
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - GlobeNewswire Inc.
Corcept Therapeutics (CORT) Climbs 19.7% as Lifyorli Gets FDA OK - Insider Monkey
'Moments like this don't happen every day': Ovarian cancer drug from Peninsula company wins FDA approval - The Business Journals
Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday - The Globe and Mail
Corcept Therapeutics Receives FDA Approval for Lifyorli - Intellectia AI
CORCEPT THERAPEUTICS INCORPORATED (CORT) - MSN
Early FDA wins: Corcept’s Lifyorli, Denali’s Avlayah - BioWorld MedTech
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss - GlobeNewswire Inc.
CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $110 - Moomoo
[144] CORCEPT THERAPEUTICS INC SE... | CORT SEC FilingForm 144 - Stock Titan
CORT: HC Wainwright Lowers Price Target to $60, Maintains Buy Ra - GuruFocus
HC Wainwright Has Lowered Expectations for Corcept Therapeutics (NASDAQ:CORT) Stock Price - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) Shares Up 10.3%What's Next? - MarketBeat
Corcept Therapeutics (CORT) Gains FDA Nod for Lifyorli in Cancer Treatment - GuruFocus
Corcept Therapeutics Sees Activity Surge as Insider Buys Boost Investor Confidence - StocksToTrade
FDA clears Corcept (CORT) Lifyorli combo for platinum-resistant ovarian cancer - Stock Titan
Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer - Reuters
FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer - Hastings Tribune
US Stocks: Corcept Therapeutics shares surge 32% as lead drug gets FDA nod for ovarian cancer - The Economic Times
Corcept Therapeutics (CORT) Sees Significant Surge Amid Market G - GuruFocus
Corcept Therapeutics Stock Soars as Insider Buys Spur Market Interest - timothysykes.com
Corcept Therapeutics (CORT) Gains as FDA Approves Cancer Drug - GuruFocus
What's Behind The Jump In Corcept Therapeutics Stock? - Benzinga
Corcept Therapeutics surges as investors focus on a sizable insider buy and relacorilant’s next regulatory catalyst - Quiver Quantitative
Corcept Therapeutics (CORT) Jumps 43% Following FDA Approval of Key Drug - GuruFocus
US FDA approves Corcept Therapeutics' drug for hard-to-treat ovarian cancer - marketscreener.com
Corcept Therapeutics (CORT) Surges 10% Following FDA Approval of Cancer Treatment - GuruFocus
FDA Approves Corcept Therapeutics' (CORT) New Cancer Treatment - GuruFocus
Corcept Therapeutics stock surges on FDA cancer drug approval By Investing.com - Investing.com Canada
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers - CancerNetwork
Deadline Approaching for Investors of Corcept Therapeutics, Inc. (CORT)Contact Kaplan Fox Before April 21, 2026 - The National Law Review
Corcept Therapeutics (NASDAQ:CORT) Insider Sells $423,729.67 in Stock - MarketBeat
Assessing Corcept Therapeutics (CORT) Valuation After Recent Share Price Weakness And User Fair Value Debate - Yahoo Finance
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - GlobeNewswire Inc.
Kaplan Fox Continues to Alert Investors of a Securities Class Act - The National Law Review
Corcept therapeutics exec Guyer sells $423,729 in shares By Investing.com - Investing.com Australia
CORT DEADLINE NOTICE: Corcept Therapeutics Incorporated - GlobeNewswire
Corcept therapeutics exec Guyer sells $423,729 in shares - Investing.com
[Form 4] CORCEPT THERAPEUTICS INC Insider Trading Activity - Stock Titan
Corcept (CORT) CDO exercises options and sells 11,767 shares - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT - ChartMill
Shareholders who lost money in shares of Corcept Therapeutics (NASDAQ: CORT) should contact Wolf Haldenstein immediately - Finviz
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss - ChartMill
Bronstein, Gewirtz & Grossman LLC Urges Corcept - GlobeNewswire
CORT Shareholder Alert: April 21, 2026 Lead Plaintiff Deadline i - GuruFocus
CORT Shareholder Alert: April 21, 2026 Lead Plaintiff Deadline in Corcept Therapeutics Incorporated Securities Class Action Lawsuit -- The Gross Law Firm - PR Newswire
CORT Technical Analysis | Trend, Signals & Chart Patterns | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Concorde International Group Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Levi & Korsinsky Reminds Corcept Therapeutics Incorporated - GlobeNewswire
Shareholders who lost money in shares of Corcept - GlobeNewswire
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud ... - Caledonian Record
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Corcept Therapeutics Incorporated Investors - GlobeNewswire
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
1.82%
자본화:
|
볼륨(24시간):